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Background: Rheumatoid arthritis is a systemic inflammatory disease characterized by synovitis and the destruction
of articular structures in multiple joints. Methotrexate is recommended as an anchor drug for rheumatoid arthritis
treatment to achieve the therapeutic goal of reducing damage to joints and improving clinical score. However,
several studies have shown that methotrexate has been associated with the development of lymphoproliferative
disorders, namely methotrexate-associated lymphoproliferative disorders. On the other hand, primary central nervous
system lymphoma is an aggressive disease with poor prognosis. Both methotrexate-associated lymphoproliferative
disorders and primary central nervous system lymphoma are reported to be associated with Epstein-Barr virus.
Case presentation: A Japanese female patient of between 60 and 70 years of age with rheumatoid arthritis was
admitted to our hospital because of sudden convulsion and impaired consciousness. Just before admission, she was
treated with adalimumab and methotrexate. Contrast-enhanced computed tomography scan showed a densely stained
mass with surrounding edema in both frontal lobes and the left nucleus basalis, and enlarged lymph nodes in the right
supraclavicular fossa. We performed a biopsy of the right cervical lymph node, but could not establish a histopathological
diagnosis. In situ hybridization showed the presence of Epstein Barr virus, therefore we diagnosed this case as
methotrexate-associated lymphoproliferative disorders mediated by Epstein Barr virus after considering the
drug history of the patient. After we discontinued methotrexate, patient symptoms gradually improved. The
masses at both frontal lobes and the left nucleus basalis were gradually regressed.
Conclusion: Since the frequency of methotrexate use and the maximum dosage has been increasing,
particular attention should be paid to the development of methotrexate-associated lymphoproliferative
disorders in rheumatoid arthritis patients who are treated with methotrexate.
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Rheumatoid arthritis (RA) is a systemic inflammatory
disease that is characterized by inflammation of the syn-
ovial membrane and extensive, progressive destruction
of articular structures in multiple joints. The therapeutic
goal of RA is to control such tissue damage and to im-
prove long-term prognosis. Methotrexate (MTX) is the* Correspondence: h_kizu@med.kagawa-u.ac.jp
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unless otherwise stated.anchor drug for RA treatment, and is expected to sup-
press the articular destruction. However, several studies
have shown that patients with RA have a high risk of on-
set of lymphoproliferative disorders (LPD) [1], and MTX
has been associated with the development of these
disorders [2]. In 2008, according to the World Health
Organization (WHO) Classification of Tumours of
Haematopoietic and Lymphoid Tissues, LPD induced
in immunodeficient patients treated with MTX is spe-
cifically defined as MTX-associated LPD (MTX-LPD)
[3]. Characteristically, MTX-LPD is reported to regressal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Additionally, an association with Epstein-Barr virus
(EBV) is indicated [5]. However, primary central nervous
system lymphoma (PCNSL) is aggressive and has a poor
prognosis [6]. Several reports have indicated that PCNSL is
also related to EBV infection, and EBV-related PCNSL
occurs more frequently in acquired immunodeficiency syn-
drome (AIDS) patients and organ transplant recipients with
severely decreased immunocompetence [7]. However, EBV-
related PCNSL rarely occurs in patients treated with im-
munosuppressive therapy. Herein, we describe a RA patient
treated with MTX who developed MTX-associated and
EBV-related PCNSL.
Case presentation
A Japanese female patient of between 60 and 70 years of
age was admitted to the emergency room in our hospital
because of sudden convulsion and impaired conscious-
ness in September 2012. She had been diagnosed with
RA two decades earlier. She began MTX therapy in
2005, and etanercept was added the next year, but was
then changed to adalimumab (ADA) in 2009. Just before
admission to our hospital, she was undergoing treatment
with ADA (40 mg/2 weeks), MTX (14 mg/week), and pre-
donisolone (PSL) (2 mg/day). In the emergency room, herTable 1 Laboratory data upon hospital admission
CBC Biochemistry Im
WBC 14730 /μl CRP 0.81 mg/dl Ig
Neu. 64 % TP 7.7 g/dl Ig
Lym. 24 % Alb 4.4 g/dl Ig
Mono. 11.5 % BUN 13 mg/dl C
Eos. 0.5 % Cr 0.6 mg/dl C
Baso. 0 % eGFR 75.99 ml/min. C
RBC 391 x104/μl T-bil 0.7 mg/dl A
Hb 12.3 g/dl AST 25 IU/l R
Hct 36.8 % ALT 12 IU/l M
Plt 25.8 x104/μl ALP 246 IU/l S
γGTP 27 IU/l S
LDH 306 IU/l M
A
Na 143 mEq/l P
A
K 4.4 mEq/l s
Cl 105 mEq/l
Ca 9.3 mEq/l
White blood cell count was elevated, and C-reactive protein and lactate dehydrogelevel of consciousness was E1V1M1 on the Glasgow
Coma Scale. Additionally, her upper and lower limbs
had a convulsive seizure. Although she did not have
anisocoria, her eyeballs were deviated to the left side.
After we administered diazepam, her convulsions were
improved. However, relapse occurred within a short
duration, and the patient was therefore admitted to
the intensive care unit.
On admission, hematological and biochemical testing
(Table 1) revealed an elevated white blood cell count to
14730 per microliter (neutrophils, 64.0%; lymphocytes,
24.0%). C-reactive protein and lactate dehydrogenase
were also increased to 0.81 mg/dl (normal range; <0.2
mg/dl) and 306 IU/l (normal range; 110〜220 IU/l), re-
spectively. Immunological test results were within almost
normal ranges, except for rheumatoid factor (RF; 64 IU/ml,
normal range; <15 U/ml). Procalcitonin and beta-D-glucan
were negative, and ferritin and soluble interleukin-2 recep-
tor were within normal ranges. EBV antibody showed a pat-
tern indicative of previous infection (EB-VCA-IgG, 160
titer; EBV-VCA-IgM, negative; anti-EBNA, 80 titer). Cranial
computed tomography (CT) scan showed low density
areas in the frontal lobes of both sides and the nucleus
basalis of the left side (Figure 1). Convulsions disap-
peared following repeated administration of diazepam.munology Infection
G 1335 mg/dl PCT <0.02 ng/ml
A 113 mg/dl β-D <5.0 pg/ml
glucan
M 103 mg/dl EBV-VCA 0.15
IgG
3 155.9 mg/dl EBV-VCA negative
IgM
4 27.2 mg/dl EBNA 0.1
H50 63.8 U/ml T-SPOT Tb negative
NA 1:40, Ho.
F 64 IU/ml
MP-3 33.2 ng/ml ABG (O2; 3 L)
S-A Ab 10.1 U/ml pH 7.29
S-B Ab 8.9 U/ml pCO2 49 Torr
PO- <3.0 IU/ml pO2 74 Torr
NCA
R3- <3.5 IU/ml HCO3 24.3 mmol/l
NCA
IL-2R 391 U/ml BE −3.4 mmol/l
SpO2 94.8 %
nase were increased.
Figure 1 Cranial computed tomography scan on admission. Arrows indicated low density areas at the frontal lobes of both sides and the
nucleus basalis of left side.
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of severe respiratory depression. Additionally, we dis-
continued MTX and ADA, and increased PSL dose to
10 mg/day.
On the sixth day after admission, we performed a
contrast-enhanced CT scan, which showed a densely
stained mass with surrounding edema in the left frontal
lobes and nucleus basalis, and enlarged lymph nodes in
the right supraclavicular fossa (Figure 2). Furthermore,
the accumulation in swollen lymph nodes was detected
on fluorodeoxyglucose (FDG) positron emission tomog-
raphy (Figure 3). Therefore, we performed a biopsy of
the right cervical lymph node.
Histopathological examination of the right cervical
lymph node showed the disappearance of follicle struc-
ture and dispersed Hodgkin-like large cells with small
lymphocytes. These large cells were positive for CD30,
Bob1 and Oct2, undeterminable for CD20 and PAX5,Figure 2 Contrast-enhanced computed tomography scan on the sixth
masses with surrounding edema at the left frontal lobe, and (b) circle showand negative for CD15. This finding differed from typical
Hodgkin lymphoma, which generally has immunoreac-
tivity for CD30, CD15, and PAX5 (Figure 4 a–e). Many
of the small lymphocytes were CD20-positive cells.
However, these were negative for MIB-1, and IgH recon-
stitution was not observed by polymerase chain reaction,
therefore we could not diagnose this case as B-cell
lymphoma. In situ hybridization showed EBV-encoded
ribonucleic acid (EBER) in the nuclei of lymphoma cells
(Figure 4f ). Consequently, we could not establish a
histopathological diagnosis and therefore diagnosed this
case as MTX-associated LPD after considering the drug
history of the patient.
After withdrawal of MTX, patient symptoms gradually
improved. The masses at both frontal lobes and the left
nucleus basalis, and the lymphadenopathy in the right
supraclavicular fossa were gradually reduced, as observed
by CT scan (Figure 5) and there was no accumulation ofday after admission. (a) Arrow indicated showed densely stained
ed many swollen lymph nodes in the right supraclavicular fossa.
Figure 3 Fluorodeoxyglucose positron emission tomography/computed tomography scan. Arrow and circle indicated the accumulation of
fluorodeoxyglucose in the swollen lymph nodes of the right supraclavicular fossa.
Figure 4 Biopsy of swollen lymph nodes in the right supraclavicular fossa. Hematoxylin and eosin staining showed (a) the disappearance
of follicle structure, and (b) dispersed Hodgkin-like large cells with small lymphocytes. (c)-(e) Immunostaining for CD30, Bob1 and Oct2 showed
positive large cells. (f) In situ hybridization showed Epstein-Barr virus encoded ribonucleic acid in the nuclei of lymphoma cells.
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Figure 5 Cranial computed tomography scan after the withdrawal of methotrexate. The masses of (A) right frontal lobe, (B) left frontal
lobe, and (C) left nucleus basalis were gradually reduced.
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salazosulfapyridine (1000 mg/day) for RA, and no recur-
rence of lymphoma was observed more than one year after
the discontinuation of MTX.
Discussion
MTX is an important drug used for the treatment of
RA. Hence, over time, the frequency of MTX use and
the maximum dosage has been increasing. However, sev-
eral studies have reported that LPD more readily de-
velops in immunodeficient patients treated with MTX
[2]. The characteristics of MTX-LPD are that 1) lymph-
oma regresses spontaneously following the withdrawal of
MTX treatment [4], 2) MTX-LPD is associated with
EBV seropositivity [5], and 3) histological findings
show various tissue types including diffuse large B-cell
lymphoma, Hodgkin lymphoma, polymorphic-LPD, and
Hodgkin like-lymphoma [8].
EBV is an oncogenic virus associated with several
malignant diseases such as Burkitt’s lymphoma, non-
Hodgkin lymphoma, and so on [9]. These malignancies
are usually considered to be the result of virus reactiva-
tion [10]. EBV was demonstrated in approximately 40%
of MTX-LPD cases, and most of them regress spontan-
eously [3]. The mechanism of MTX-LPD is that the im-
munosuppressive state induced by MTX treatment may
allow reactivation of EBV as normal anti-virus surveil-
lance is impaired, and some MTX-LPDs associated withEBV may regress after MTX withdrawal by the restor-
ation of normal immunity [4].
In our case, a RA patient with a history of MTX ad-
ministration had a sudden convulsion, multiple brain tu-
mors, and lymphadenopathy observable by CT scan. We
could not make a definite diagnosis by histological find-
ings of cervical lymph node biopsy, which demonstrated
Hodgkin-like large cells and many CD20-positive lym-
phocytes. Additionally, EBERs were detected in the
nuclei of lymphoma cells. Therefore, we diagnosed MTX-
LPD mediated by EBV.
However, we could perform the biopsy not from cen-
tral nervous system (CNS) lesion but from cervical
lymph node. In fact, we could not judge whether the
CNS tumor was MTX-LPD or not. After withdrawal of
MTX, symptoms gradually improved, and both the CNS
tumors and cervical lymphadenopathy remarkably de-
creased, as observed by cranial CT scan. Hence, we
could conclude that these tumors are from same origin.
In this case, ADA was also administered but discontinued
after onset of convulsions, concomitantly with MTX. How-
ever, Ramiro et al. indicated that patients treated with an
anti-tumor necrosis factor (TNF) inhibitor did not have an
increased risk of lymphoma [11]. Burmester et al. showed
that the greater rate of lymphoma occurrence observed
during ADA trials in patients with RA was within the range
that might be expected in a similar RA population not
treated with anti-TNF therapy [12]. Therefore, in the
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caused by MTX and not ADA.
PCNSL occurs in brain, spinal cord, eyeball, cranial
nerve, and meninges without affecting other organs. It is
aggressive, and almost always of B-cell origin [6]. Al-
though PCNSL is a rare lymphoma that accounts for
only approximately 3% of all primary brain tumors, the
incidence tends to increase within the last 10 years.
High-dose MTX and radiation therapy is recommended
as a treatment of PCNSL [13]. Furthermore, previous re-
ports uphold the relationship between EBV and PCNSL
[10,14-16]. In general, EBV-related PCNSL has a poor
prognosis. Moreover, it occurs in some AIDS patients,
organ transplant recipients and a few immunocompetent
individuals [7]. Furthermore, there are a few reports that
PCNSLs occurred in patients treated with immunosup-
pressive drugs. Kleinschmidt-DeMasters et al. showed
four cases of EBV-related PCNSL occurring in older pa-
tients who were treated with immunosuppressive drugs
(MTX, mycophenolate mofetil, azathioprine, PSL, cyclo-
phosphamide, and so on). In one case, in which the pa-
tient was treated with MTX, the lymphoma improved
following the cessation of MTX and specific treatment
for the toxoplasmosis [17]. Her neurological deficits
markedly improved, but she developed renal failure and
died on approximately 3 months later. Migita et al. also re-
ported a patient with RA who developed an EBV-related
PCNSL during treatment with MTX. They underwent
surgical resection and MTX withdrawal, resulting in MTX-
LPD improvement without any recurrence [18].
In our case, PCNSL markedly regressed only by the
discontinuation of MTX, and there is presently no recur-
rence. This finding confirms the potentiality of the
spontaneous nature of MTX-LPD regression following
cessation of MTX treatment.Conclusion
We have presented a rare case in which a RA patient
treated with MTX developed MTX-associated, EBV-
related PCNSL, which regressed markedly upon the
withdrawal of MTX. Since current treatment strategies
for RA recommend MTX as a first choice therapy in
early stages of disease, the frequency of MTX use and
the maximum dosage has been increasing. Therefore,
we need to pay attention to the development of MTX-
LPD for RA patients who are treated with MTX.Consent
Written informed consent was obtained from the pa-
tient for publications of this Case Report and any
accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of the
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